The market for Gunshot Injuries Treatment Products is expected to reach US$ XX Bn in 2026.
Wounds inflicted by gunshots are very painful and life-threatening if not given immediate medical attention. Hemorrhage or profuse blood loss is the chief cause of mortality seen in military warfare. Rapid and effective management of hemorrhage is a lifesaving endeavor. There is currently an increase in the number of criminal violence and accidents occurring, which leads to mass killing and traumatic injury, propelling the growth of the gunshot wound injury treatment products market. Gunshot wound management is a critical procedure that involves observation, such as determining if there is a flash bleed, checking vital signs, and investigating if there is a burn to tissues, pallor, or swelling.
The Chicago Tribune, in its latest survey, has reported that each week in the United States, approximately 1,600 people are treated in trauma centers for gunshot wounds. The Brady report for 2016 states that in the United States, each year, 34,000 people die due to gunshot injuries, while 81,000 people survive. Post-World War II, the United States has been engaged in several wars in the Middle East and Afghanistan and has suffered tremendous casualties, with soldiers succumbing to gunshot wounds. In April 2014, the USFDA approved XSTAT 30, manufactured by RevMedx, Inc., a revolutionary hemostatic device that is used for the treatment of shrapnel and gunshot wounds. It consists of small groups of expanding sponges containing x-ray markers and is directly injected into the wound cavity. It temporarily creates a barrier for blood loss, providing hemostatic pressure, and is effective for 4 hours before the patient receives medical surgery.
Product
Geography
The key players set to make a mark in the global gunshot wounds market are RevMedx, Inc. and Baxter Healthcare Corporation.
The market for Gunshot Injuries Treatment Products is expected to reach US$ XX Bn in 2026.
The Gunshot Injuries Treatment Products market is expected to see significant CAGR growth over the coming years,at XX%.
The report is forecasted from 2018-2026.
The base year of this report is 2017.